How much funding has Verastem raised?

Verastem has raised $392.5M in total funding, most recently a Corporate Round.

Who are Verastem's investors?

Verastem's investors include Bessemer VP, Advanced Technology Ventures, MPM Capital, Eastern Advisors, Cardinal Partners.

Where is Verastem headquartered?

Verastem is headquartered in Boston, Massachusetts, United States.

What industry is Verastem in?

Verastem operates in Biopharmaceutical, Healthcare, Biotech.

Verastem

formerly Verastem OncologyIPO

Precision targeting of RAS/MAPK pathway-driven cancers

Public · Boston, United States · Founded 2010 · $392.5M raised

Biopharmaceutical

Healthcare

Biotech

Headquarters: Boston, Massachusetts
Employees: 51–200
Founded: 2010
Business Model: B2B
Website: verastem.com

Total Funding: $392.5M
Last Round: $90.0M Corporate RoundNov 2025
Rounds: 8
Type: Public

About

Verastem Oncology is a biopharmaceutical company focused on developing and commercializing medicines to improve the lives of patients with cancer. The company's pipeline targets the RAS/MAPK signaling pathway, which drives cell survival and tumor growth, through novel small molecule inhibitors. This includes KRAS G12D inhibition, RAF/MEK inhibition, and FAK inhibition to address resistance mechanisms. Verastem achieved an FDA-approved treatment (AVMAPKI FAKZYNJA CO-PACK) for KRAS-mutant recurrent low-grade serous ovarian cancer, the first approved therapy for this indication. The company trades on NASDAQ under the symbol VSTM.

Summary

Verastem is a Biopharmaceutical company based in Boston, United States, founded in 2010. It has raised $392.5M in total across 8 rounds, most recently a $90.0M Corporate Round round in Nov 2025. Investors include Bessemer VP, Advanced Technology Ventures and MPM Capital.

LinkedIn X (Twitter)